MARKET

GLYC

GLYC

Glycomimetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6001
-0.0091
-1.49%
After Hours: 0.6150 +0.0149 +2.48% 18:50 05/26 EDT
OPEN
0.6188
PREV CLOSE
0.6092
HIGH
0.6300
LOW
0.6001
VOLUME
188.65K
TURNOVER
0
52 WEEK HIGH
2.830
52 WEEK LOW
0.5357
MARKET CAP
31.44M
P/E (TTM)
-0.4877
1D
5D
1M
3M
1Y
5Y
Recap: GlycoMimetics Q1 Earnings
  GlycoMimetics (NASDAQ:GLYC) reported its Q1 earnings results on Thursday, April 28, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 04/28 12:51
BRIEF-GlycoMimetics Reports Highlights and Financial Results for Q1 2022
reuters.com · 04/28 11:53
GlycoMimetics GAAP EPS of -$0.28 beats by $0.03
GlycoMimetics press release (NASDAQ:GLYC): Q1 GAAP EPS of -$0.28 beats by $0.03. Cash and cash equivalents of $76.5M. There was no revenue recognized during the quarter. “During the first quarter,
Seekingalpha · 04/28 11:43
-- Earnings Flash (GLYC) GLYCOMIMETICS Posts Q1 Loss $-0.28, vs. Street Est of $-0.32
MT Newswires · 04/28 07:51
GlycoMimetics's Earnings: A Preview
GlycoMimetics (NASDAQ:GLYC) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that GlycoMimetics will report an earnings per share (EPS) of $-0.31.
Benzinga · 04/27 19:58
GlycoMimetics Q1 2022 Earnings Preview
GlycoMimetics (NASDAQ:GLYC) is scheduled to announce Q1 earnings results on Wednesday, April 27th, after market close. The consensus EPS Estimate is -$0.32 (-14.3% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 04/27 16:48
GlycoMimetics Earnings Conference Call Is Coming Up, Here's What You Need To Know
GlycoMimetics (NASDAQ:GLYC) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results. How to Attend GlycoMimetics (GLYC) Conference Call Follow this link to access the live webcast.
Benzinga · 04/26 17:02
Stocks That Hit 52-Week Lows On Monday
    On Monday, 466 companies hit new 52-week lows.
Benzinga · 04/18 15:40
More
No Data
Learn about the latest financial forecast of GLYC. Analyze the recent business situations of Glycomimetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GLYC stock price target is 10.67 with a high estimate of 15.00 and a low estimate of 3.000.
High15.00
Average10.67
Low3.000
Current 0.6001
EPS
Actual
Estimate
-0.27-0.20-0.14-0.07
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 102
Institutional Holdings: 40.64M
% Owned: 77.57%
Shares Outstanding: 52.39M
TypeInstitutionsShares
Increased
9
61.42K
New
3
115.68K
Decreased
19
2.22M
Sold Out
6
235.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Timothy Pearson
President/Chief Executive Officer/Director
Harout Semerjian
Co-Founder/Senior Vice President/Chief Scientific Officer
John Magnani
Chief Financial Officer/Senior Vice President - Finance
Brian Hahn
Senior Vice President
Armand Girard
Senior Vice President
Bruce Johnson
Director
Rachel King
Independent Director
Patricia Andrews
Independent Director
Mark Goldberg
Independent Director
Scott Jackson
Independent Director
Daniel Junius
Independent Director
Scott Koenig
No Data
No Data
About GLYC
GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of novel glycomimetic. Its drug candidates include Uproleselan, GMI-1359, Rivipansel, GMI-1687, and Galectin Antagonists. Its Uproleselan a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), a life-threatening hematologic cancer, and potentially other hematologic cancers. The GMI-1359 targets E-selectin and a chemokine receptor. Its Rivipansel is a glycomimetic drug candidate that act as , a pan-selectin antagonist for treatment of vaso-occlusive crisis. It has designed antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. Galectin Antagonists includes Galectin-3, which is a carbohydrate-binding protein.

Webull offers kinds of GlycoMimetics Inc stock information, including NASDAQ:GLYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLYC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLYC stock methods without spending real money on the virtual paper trading platform.